Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Hotta, K.
Kiura, K.
Takigawa, N.
Tabata, M.
Fujiwara, Y.
Tanimoto, M.
机构：
[1] Okayama Univ, Grad Sch Med, Dept Hematol Oncol & Resp Med, Okayama, Japan
[2] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[3] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan
[4] Okayama Univ, Tsuyama Cent Hosp, Okayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7624
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7624
引用
收藏
页数：1
相关论文
共 50 条
  • [31] THE VALIDITY OF OBJECTIVE RESPONSE RATE AS A SURROGATE FOR PROGRESSION-FREE AND OVERALL SURVIVAL IN THE EVALUATION OF FIRST LINE CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Goring, S. M.
    Briggs, A.
    Penrod, J. R.
    Fan, S.
    Waser, N.
    Thompson, J.
    Wilson, J. B.
    Wang, S.
    Korytowsky, B.
    Chirita, O.
    Hertel, N.
    Yuan, Y.
    VALUE IN HEALTH, 2017, 20 (09) : A421 - A421
  • [32] Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone
    Zhigang Wei
    Xin Ye
    Xia Yang
    Guanghui Huang
    Wenhong Li
    Jiao Wang
    Xiaoying Han
    Medical Oncology, 2015, 32
  • [33] Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone
    Wei, Zhigang
    Ye, Xin
    Yang, Xia
    Huang, Guanghui
    Li, Wenhong
    Wang, Jiao
    Han, Xiaoying
    MEDICAL ONCOLOGY, 2015, 32 (02)
  • [34] Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
    Masayuki Aboshi
    Masayuki Kaneko
    Mamoru Narukawa
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 839 - 848
  • [35] Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
    Aboshi, Masayuki
    Kaneko, Masayuki
    Narukawa, Mamoru
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (05) : 839 - 848
  • [36] SIMULATION AND COMPARISON OF PROGRESSION-FREE SURVIVAL (PFS) AMONG PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING SEQUENTIAL THERAPY
    Chouaid, C.
    Walzer, S.
    Lister, J.
    Gultyaev, D.
    Vergnenegre, A.
    de Marinis, F.
    Meng, J.
    de Castro, J.
    Crott, R.
    Kleman, M.
    Ngoh, C. A.
    VALUE IN HEALTH, 2014, 17 (03) : A70 - A70
  • [37] Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
    Soussi, Ghassen
    Racil, Hajer
    Bacha, Saoussen
    Rouhou, Sana Cheikh
    Zidi, Asma
    Ayadi, Aida
    Chaouch, Nawel
    Chabbou, Abdellatif
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [38] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH SECOND LINE ERLOTINIB/GEFITINIB WHO FAILED TO PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Hudoyo, Ahmad
    Andarini, Sita
    RESPIROLOGY, 2015, 20 : 101 - 101
  • [39] BASELINE POPULATION CHARACTERISTICS AND THE ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ADVANCED NON SMALL CELL LUNG CANCER PATIENTS
    Kulakova, M.
    Hashim, M.
    Pfeiffer, B.
    Postma, M.
    Heeg, B.
    VALUE IN HEALTH, 2017, 20 (09) : A420 - A421
  • [40] Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
    Takaya Yamamoto
    Yoko Tsukita
    Yu Katagiri
    Haruo Matsushita
    Rei Umezawa
    Yojiro Ishikawa
    Noriyoshi Takahashi
    Yu Suzuki
    Kazuya Takeda
    Eisaku Miyauchi
    Ryota Saito
    Yoshiyuki Katsuta
    Noriyuki Kadoya
    Keiichi Jingu
    BMC Cancer, 22
12345